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Drug induced liver injury (DILI) is an idiosyncratic adverse drug reaction leading to severe liver damage. Kupffer cells (KC) sense
hepatic tissue stress/damage and therefore could be a tool for the estimation of consequent effects associated with DILI. Aim of the
present study was to establish a human in vitro liver model for the investigation of immune-mediated signaling in the pathogenesis
of DILI. Hepatocytes and KC were isolated from human liver specimens. The isolated KC yield was 1.2 ± 0.9 × 106 cells/g liver
tissue with a purity of >80%. KC activation was investigated by the measurement of reactive oxygen intermediates (ROI, DCF
assay) and cell activity (XTT assay). The initial KC activation levels showed broad donor variability. Additional activation of KC
using supernatants of hepatocytes treated with hepatotoxic drugs increased KC activity and led to donor-dependent changes in
the formation of ROI compared to KC incubated with supernatants from untreated hepatocytes. Additionally, a compound- and
donor-dependent increase in proinflammatory cytokines or in anti-inflammatory cytokines was detected. In conclusion, KC related
immune signaling in hepatotoxicity was successfully determined in a newly established in vitro liver model. KC were able to detect
hepatocyte stress/damage and to transmit a donor- and compound-dependent immune response via cytokine production.
1. Introduction
Drug induced liver injury (DILI) represents an idiosyncratic
adverse drug reaction responsible for severe patient mor-
bidity and mortality and in consequence for the withdrawal
of about 20% of new drugs from the market [1, 2]. In the
USA, about 60% of all cases of acute liver failure and 10–20%
of fulminant or subfulminant hepatitis originate from drug
toxicity [3, 4]. Milder forms of DILI are assumed to occur in
a high number of unknown cases. Therefore, the incidence
and prevalence of DILI are only partially known [5]. The
idiosyncratic origin of DILI and its unspecific reactions are
the reason why it is still difficult to predict the potential risk
of DILI in preclinical drug testing [6]. In vivo animal studies
are not suitable for reflecting the idiosyncratic nature of DILI
and its low frequency would require very high numbers of
animals to detect DILI events [2, 7].
Additionally, the occurrence of immune tolerance reac-
tions in the liver can influence DILI consequences in vivo
[8]. In vitro studies using human cells could bypass systemic
tolerance reactions and thus better reflect the human situ-
ation. However, it is known that many in vivo hepatotoxic
effects are not detected in primary humanhepatocytes (PHH)
monocultures, which are however considered to be the gold
standard of in vitro liver models. The lack of a physiological
3D environment and the absence of nonparenchymal cells are
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discussed as possible reasons for an insufficient reflection of
DILImechanisms in conventional 2Dhepatocyte cultures [9–
11].
The mechanisms of DILI are not yet sufficiently clarified.
According to different hypotheses, an immune-mediated
mechanism is considered to be a major factor in its patho-
genesis [2, 12, 13]. This mechanism of action starts with the
hepatic biotransformation of drugs, which can lead to the
production of reactive metabolites [14]. Hydroxylation by
cytochrome P450 enzymes especially can produce hydro-
quinone, benzoquinoneimine, and catechol structures, which
are of electrophilic nature. Such compounds disturb the redox
balance and induce the generation of reactive oxygen species
(ROS) leading to oxidative stress. Additionally, electrophilic
metabolites can react with endogenous nucleophilic groups
of DNA and proteins. The reaction with proteins leads to the
formation of haptens. If released, these haptens can be identi-
fied by immune cells due to their antigenic character [12, 13],
causing sensitizing reactions or, at worst, the induction of
autoimmune diseases [15].
Kupffer cells (KC) are the primary macrophage popu-
lation of the liver. They are on the one hand part of the
scavenger system, which is responsible for systemic blood
clearance and on the other hand responsible for detection of
local tissue damage. In this function, KC are active in phago-
cytosis of cell debris, soluble macromolecules, and colloids
as well as endogenous and foreign proteins [16]. Besides the
recognition of cellular stress and cell death in hepatotoxic
events, KC also fulfill a transmitter role in the communication
to the immune system by antigen presentation and cytokine
secretion [17]. KC activation by lipopolysaccharides (LPS),
cell debris, haptens, or cytokines is accompanied by intra-
cellular activation of the NF-𝜅B signaling pathway mediated
by reactive oxygen intermediates (ROI) [18]. Once activated,
KC can differentiate into M1 type and M2 type macrophages
depending on the signals received and on the genetic back-
ground. M1-KC play an important role in innate immunity
and proinflammatory reactions. This inflammatory cell type
is supported by TH1 cells. The alternative M2 response
is depending on TH2 cells and ends in tissue-protective
reactions. M2-KC promote maturation and activation of
other KC, enhance tissue repair, and have a beneficial effect
on vascular growth and nutrient homeostasis [19, 20]. Each
KC class is associatedwith specific cytokines.M1-KC produce
the proinflammatory cytokines IL-6, IL-8, and TNF-𝛼, while
M2-KC are associated with the anti-inflammatory cytokines
IL-4, IL-5, and IL-10 [21–23]. Additionally, prostaglandin
E
2
(PGE-2) can be released, which inhibits TNF-𝛼 and IL-
6 production by KC in an autocrine feedback loop and
attenuates the induction of acute-phase proteins [24]. PGE-2
is therefore associated with the M2-KC response rather than
with the M1-KC response.
Two well-known hepatotoxic compounds responsible
for the induction of DILI are acetaminophen (APAP) and
diclofenac (DIC) [3]. Both compounds are nonsteroidal
anti-inflammatory drugs (NSAID). APAP is transformed by
cytochrome P450 (CYP) 2E1 and CYP1A1 to the reactive
metabolite N-acetyl-p-benzoquinone imine [23]. APAP is
known for the induction of hepatic oxidative stress and
in consequence glutathione depletion leading to acute liver
failure. Protein adduct formation has also been described
but plays a minor role in APAP hepatotoxicity [25]. DIC is
metabolized by CYP2C9 and CYP3A4 to two hydroxylated
metabolites consequently transformed in secondary reac-
tions into metabolites with benzoquinone imine structure
[26]. Both metabolites have been shown to react with pro-
teins. Hapten formation correlates with the occurrence of
sensitization reactions towards DIC. Beside hapten forma-
tion, the generation of ROS is also described but is of minor
clinic relevance compared to APAP [23].
Aim of the present study was the establishment of a
human in vitro KC culture model for the investigation
of immune-mediated signaling in hepatic pro- and anti-
inflammatory reactions involved in the pathogenesis of DILI.
For the present study, PHH and KC were isolated from
human liver resectates using a two-step collagenase perfusion
technique followed by selective separation steps to get puri-
fiedPHHandKC fractions. KCwere identified and character-
ized by morphological und functional investigations. Opti-
mization of KC culture conditions allowed for a cultivation
for up to 5 d. The known hepatotoxic drugs APAP and DIC
were used at subtoxic concentrations to simulate a DILI-
like event in PHH cultures. Supernatants of drug-treated
PHH were then used to stimulate KC cultures. While most
liver models for hepatotoxicity testing usually need high con-
centrations leading to definite toxic effects, this new model
allows for detecting hepatotoxic cell stress also in a subtoxic
concentration range.
2. Material and Methods
2.1. Chemicals. Thehepatocyte culturemediumwas based on
Williams’ Medium E with GlutaMAX (Gibco, Paisley, UK),
supplemented with 10% FCS (Gibco), 32mU/mL Insulin
(Sanofi Aventis, Frankfurt am Main, Germany), 15mM
HEPES, 0.1mM MEM NEAA (100×), 1mM pyruvate (all
by Gibco), and 1mg/L dexamethasone (Fortecortin, Merck,
Darmstadt, Germany).
KC culture medium was based on RPMI low glucose
(GE Healthcare, Pasching, Austria) supplemented with 10%
FCS, 1% L-glutamine, and 6.3mM N-acetyl-L-cysteine (all
by Gibco). KC starvation medium was based on RPMI low
glucose supplemented with 1% L-glutamine. All media were
supplemented with 100U/100 𝜇M penicillin/streptomycin
(Gibco) prior to use.
PBS was purchased from Gibco. Percoll, Trypan Blue,
and Hanks Balanced Salt Solution (HBSS) were provided
by Biochrom (Berlin, Germany). All other chemicals were
purchased from Sigma (Munich, Germany), if not stated
differently.
2.2. Isolation and Culture of Primary Human Hepatocytes and
Kupffer Cells. Formimicking immune-mediated reactions in
DILI, a human in vitro liver model based on primary human
liver cells was established. PHH and KC were isolated in
parallel from the same donor tissue to avoid immune reac-
tions due to incompatibility.
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PHH and KC were isolated from nontumorous human
liver tissue, which remained after partial liver resection in
patients with primary or secondary liver tumors. Addition-
ally, corresponding human blood samples were obtained and
used for production of autologous serum. Informed consent
of the patients was obtained according to the ethical guide-
lines of the Charite´-Universita¨tsmedizin Berlin.
PHH were isolated by a two-step collagenase perfusion
technique according to Nu¨ssler et al. [27]. PHH contained
in the gained cell suspension were enriched by double
centrifugation at 50×g, 5min, 4∘C.The pellet was suspended
in hepatocyte culture medium and seeded at a density of
145,000/cm2 in cell culture plates. Culture medium exchange
was performed 12 h after seeding and afterwards every 24 h.
Prior to startingAPAP orDIC treatment, the culturemedium
was exchanged against hepatocyte starvation medium.
The supernatant of the initial centrifugation of the cell
suspension was used for KC isolation [28]. To eliminate
remaining erythrocytes, the supernatant was centrifuged at
72×g, 5min, 4∘C. The supernatant, which contained the
nonparenchymal liver cells (NPC), was centrifuged at 650×g,
7min, 4∘C. The pellet consisting of KC, hepatic stellate cells,
and liver endothelial cells was resuspended in 20mL HBSS.
For enrichment of KC, the cell suspension was subjected
to a Percoll density gradient centrifugation. A two-level
gradient consisting of a 25% Percoll solution on top of a
50% Percoll solution was prepared. The cell suspension was
carefully placed on top of the 25% Percoll gradient and
centrifuged at 1800×g, 15min, 4∘C,without brake.The cells in
the interphase between 25% and 50% Percoll were collected,
washed once with HBSS, and resuspended in KC starvation
medium. The cell number and viability of the contained KC
were determined by using the Trypan blue exclusion tech-
nique. To remove remaining NPC, the selective adherence
capacity of KC on cell culture plastics was used. KC were
seeded at a density of 0.5 × 106 cells/cm2 on a 24-tissue
culture plate (Falcon BD,Heidelberg, Germany) and cultured
for 25min at 37∘C, 5% CO
2
in a humidified incubator. Not
adhered NPC were removed by washing the culture plate
with HBSS. KC were then maintained in KC culture medium
for at least 12 h overnight. The medium was replaced by KC
starvation medium on the next day and KC were cultured
at least for 4 h in that medium before the cells were used for
experiments.
2.3. Optimization of Culture Conditions. Previous studies had
shown that KC isolated from human liver tissue show a
donor-dependent initial activation [29]. Due to potentially
varying initial KC activation levels, we performed experi-
ments designed to reduce or stabilize the KC activation. KC
are activated by different factors like endogenous or foreign
proteins, LPS, or environmental changes.
To exclude additional KC activation by xenogenous
proteins contained in fetal calf serum, cultivation in KC
culturemediumwith autologous serumorwithout any serum
was tested. Autologous serum was generated by centrifuging
10mL blood from the patient at 1000×g, 10min and 4∘C.
Additionally, a potential reduction of the initial KC
activation by addition of antioxidants to KC cultures was
investigated. Therefore, KC were cultured for up to 108 h by
using KC culture medium supplemented with or without
10mM 𝑛-acetylcysteine or 10mM ascorbic acid.
2.4. Characterization of KC
2.4.1. Immunofluorescence Staining. The purity of the iso-
lated KC was determined by immunofluorescence staining
of CD68, which is a surface protein of the macrophage
lineage, including monocytes, histiocytes, giant cells, KC,
and osteoclasts. An antibody against CD68 (R&D Systems,
Minneapolis, USA) and a secondary antibody coupled with
phycoerythrin (PE) (Santa Cruz Biotechnology Inc., Heidel-
berg, Germany) were used for staining.
Additionally, the ability for phagocytosis was evaluated
by using FITS coupled latex beads (FluorisBite plain YG3.0
microspheres, Polyscience). Cell nuclei were stained with
Hoechst 33342 (Sigma-Aldrich GmbH, St. Louis, US). Images
were taken with a fluorescence microscope (Zeiss, Jena,
Germany).
2.4.2. Cell Viability/Cell Activity. In order to evaluate the
cell viability as well as changes in energy metabolism, the
cell activity was determined using the XTT assay (Roche
Diagnostics GmbH, Mannheim, Germany). The test was
performed according to the manufacturer’s protocol. After
2 h incubation time, the supernatants were transferred into
a 96-well plate and the absorbance was measured at 492 nm
in a microplate reader (FLUOstar OPTIMA, BMG Labtech,
Ortenberg, Germany).
2.4.3. Measurement of Intracellular Reactive Oxygen Interme-
diates (ROI). ROI play an essential role in signaling pathways
of inflammatory reactions. Therefore, the formation of intra-
cellular ROIwasmeasured by using the fluorogenic substance
dichlorodihydrofluorescein diacetate (DCF-DA) according
to [30] with minor modifications. The cell-permeable DCF-
DA diffuses into cells and is deacetylated by cellular esterases
and oxidized by ROI to dichlorodihydrofluorescein (DCF).
For ROS measurement, the culture medium was replaced
with RPMI medium without serum and phenol red, but
containing 20 𝜇MDCF-DA (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) followed by incubation for 30min at
37∘C, 5% CO
2
in a humidified incubator. Subsequently, the
supernatants were aspirated and the cells were incubated
with fresh medium without serum and phenol red for 1 h.
Fluorescence was measured in a microplate reader at an
excitation wavelength of 492 nm and an emission detection
of 520 nm.
2.5. Kupffer Cell Stimulation. Selective activation of KC was
performed by incubation with hepatotoxic drugs (APAP,
DIC) or using lipopolysaccharide (LPS) stimulation. For
equilibration of the KC, cells were cultured in starvation
medium for 24 h. Subsequently, KC were incubated with
100 𝜇MAPAP, 100 𝜇MDIC, or with different LPS concentra-
tions in starvation medium for further 24 h. KC activation
was determined by the measurement of ROI formation and
cell viability as described above.
4 Mediators of Inflammation
Table 1: Anamnesis data of investigated donors.
Diagnosis Sex Age BMI Notes
Healthy Adenoma F 48 29 —
Cholangiocellular carcinoma F 50 20 —
Multimorbidity
Klatskin tumor M 80 31 Hypercholesterolemia
Colorectal liver metastasis M 72 23 Coronary heart disease
Cholangiocellular carcinoma M 74 29 Diabetes, hypertension, and in situ split
Gall bladder carcinoma F 57 28 Portal vein embolisation, hypertension, and cholestasis
Cholangiocellular carcinoma F 75 24 Hypercholesterolemia
Cholangiocellular carcinoma M 61 31 Hypertension, hypercholesterolemia
Hemangioma F 43 28.4 Diabetes
Cholangiocellular carcinoma M 47 23 Terminal renal failure, hypercholesterolemia
Chronic inflammation Klatskin tumor M 72 24 Chronic inflammation, diabetes, and hypertension
Portal vein embolisation Colorectal liver metastasis F 60 — Portal vein embolisation
Colorectal liver metastasis M 57 28 Portal vein embolisation, chemotherapy
Cholestasis Cholangiocellular carcinoma F 72 22 Cholestasis
Cholangiocellular carcinoma F 77 22 Cholestasis
Chemotherapy Colorectal liver metastasis F 71 — Chemotherapy
Hepatic steatosis Hepatocellular carcinoma M 75 — Resection area, steatohepatitis
Adenoma F 32 — Diabetes, steatohepatitis
Resection area Hemangioma M 47 27 Resection area
Cholangiocellular carcinoma M 62 25 Resection area, chemotherapy
Donor A Focal nodular hyperplasia F 19 22 —
Donor B Colorectal liver metastasis M 50 23 Diabetes, smoker
Donor C Klatskin tumor M 52 25 Diabetes, portal vein embolisation
To investigate the activation of KC following hepatocyte
damage, KC were incubated with the supernatants of drug-
treated PHH from the same donor. Therefore, the PHH
were cultured for 4 h and KC for 5 h in starvation medium
for equilibration of the cells. Subsequently, the PHH were
stimulated with 100 𝜇M APAP or 100 𝜇M DIC in starvation
medium for 1 h, respectively. Then, the supernatants of the
compound-treated PHH were transferred onto the KC. After
2 h incubation time, ROI formation and cell activity were
measured as described above. Additionally, the supernatants
were collected and stored at −80∘C after freezing in liquid
nitrogen for subsequent measurement of pro- and anti-
inflammatory cytokine formation asmarker for KC response.
These experiments were performed with cells from three
independent donors and evaluated individually for each
donor (Table 1).
2.6. Cytokine ELISA. In order to evaluate inflammatory
reactions of KC, the formation of pro- and anti-inflammatory
cytokines was investigated. Tumor necrosis factor-𝛼 (TNF-
𝛼), interleukin-6 (IL-6), and interleukin-10 (IL-10) ELISA
Kits (PeproTech GmbH, Hamburg, Germany) as well as
a prostaglandin E2 (PGE-2) ELISA Kit (Thermo Fischer
Scientific, Waltham, USA) were used for the measurement
of cytokine concentrations in cell culture supernatants.
Cytokine formation was measured following the manufac-
turer’s instruction.
2.7. Statistical Analysis. Data were analyzed by one-way or
two-way ANOVA, with a 𝑡-test or a Mann-Whitney test
using Graph Pad Prism 5 software. Results are given as
means ± SEM or as median including the interquartile range,
minimum and maximum values presented as box plots.
Differences were considered as significant at 𝑃 < 0.05.
Only data from experiments performed at least three times
with cells from different donors were subjected to statistical
analysis.
3. Results
3.1. Isolation and Characterization of PHH and KC. KC
were successfully isolated from 37 different donors using the
supernatants remaining from PHH isolation. Trypan blue
staining showed that >90% of KC were viable. A yield of
1.2 ± 0.9 × 10
6 KC per gram of liver tissue was obtained.
KC were identified by immunostaining of the macrophage-
specific surface protein CD68 and by their ability for phago-
cytosis of fluorescent latex beads (Figure 1(a)). CD68-positive
and phagocytosis-positive cells were counted in relation to
total cells stained with Hoechst dye (Figure 1(b)). A purity
of 60% was obtained in the KC-rich cell suspension. The
performance of the adherence separation step increased the
purity to >80% (Figure 1(c)).
The determination of KC activity was performed directly
after the isolation procedure. Intracellular ROI levels as
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Figure 1: Identification of KC and determination of the purity of KC cultures. KC were identified by IF staining for CD68 (a) and the
phagocytosis of fluorescent latex beads (b). The percentages of CD68-positive and phagocytosis-positive cells isolated with an adherence
separation step (w ASS) or without an adherence separation step (w/o ASS) are shown in (c). Data are shown as box plots, representing the
median, the interquartile range, and minimum and maximum values. ∗ At least 𝑃 ≤ 0.0001 (unpaired 𝑡-test),𝑁 = 3, 𝑛 = 9.
mediator in the NF-𝜅B signaling pathway were measured by
the DCF assay. The measurement of the initial KC activation
revealed variable intracellular ROI concentrations in cultures
from donors with different donor anamnesis and tissue qual-
ity (Figure 2, Table 1). The lowest KC activity was detected
in healthy patients with low BMI and early tumor stages
(considered as healthy tissue). Patients with multimorbidity
or chronic inflammation showed preexisting moderate KC
activation as an indicator of chronic cell stress/damage. In
contrast, the KC from livers with tissue damage caused by
portal vein embolization, cholestasis, or recently performed
chemotherapy revealed the highest KC activation levels. The
same was true for steatotic liver or liver tissue close to the
resection margin with direct injury by cauterization, which
led to the highest KC activation levels. The comparison
betweenROI levels anddonor anamnesis indicates that donor
conditions and liver tissue quality influence the initial KC
activation, although no definitive statement can be made due
to the low numbers of donors in each group.
3.2. Experimental Setup and Evaluation of Optimal Cul-
ture Conditions. In general, cultured KC showed a loss in
cell viability associated with a decrease of ROI over 5 d
regardless of the type of serum used. The cultivation with
FCS had a slightly positive effect on cell viability, while
a slight increase of KC activation was observed compared
to serum-free cultivation or cultivation with autologous
serum (see Supplementary Figure 1 available online at
http://dx.doi.org/10.1155/2015/640631).
Cultivation of KC in the presence of the antioxidants 𝑛-
acetyl cysteine or ascorbic acid also showed an increase in
the ROI level. However, a beneficial effect on cell viability
in comparison to the control was observed during the first
12 h after seeding. N-acetyl cysteine had a stronger effect than
ascorbic acid (Supplementary Figure 2).
3.3. Compound-Dependent KC Activation. KC can be acti-
vated by a variety of stimuli. For determination of the
sensitivity of KC towards cell stress, KC were exposed to
hepatotoxic drugs (APAP, DIC) or to the known KC acti-
vating agent LPS [18]. Of special interest in this experiment
was the question, if an additional activation on top of
the initial activation is detectable. Therefore, KC cultures
were stimulated with varying concentrations of APAP, DIC,
and LPS for 24 h. At the end of the activation period, the
intracellular ROI levels weremeasured and normalized to the
cell viability.


































































































Figure 2: Initial KC activation. Initial ROI levels correlated with tis-
sue quality and donor anamnesis. Initial ROI levels were measured
in KC cultures by means of the DCF assay performed directly after
KC isolation. Data show means ± SEM.𝑁: shown in the figure.
Treatment of KC with APAP for 24 h showed for both
concentrations (0.1 and 1mM) a slight increase in the relative
oxidative stress levels by trend (Figure 3(a)). The treatment
with DIC for 24 h showed no effect for 0.1mM DIC and a
slight increase in the relative oxidative stress level for 1mM
DIC (Figure 3(b)).
The stimulation with LPS showed a tendency towards a
concentration-dependent increase in the relative ROI levels
compared to the untreated control (Figure 3(c)). The results
showed large variations due to different initial ROI values
in activation of KC from individual donors. Taken together,
for various concentrations of APAP and DIC, no statistically
significant activation was detectable. Furthermore, the pos-
itive control LPS did not show any statistically significant
KC activation. However, a clear trend for a concentration-
dependent activation was observable, which suggests that an
additional activation of preactivated KC is possible.
3.4. Response of Kupffer Cells to Hepatocyte Stress/Damage
3.4.1. Hepatocyte Stress/Damage after Stimulation with Hep-
atotoxic Drugs. For the simulation of hepatocyte stress/
damage, we treated isolated hepatocytes from 3 different
donors (Donor A, Donor B, and Donor C) with the hep-
atotoxic drugs APAP or DIC (100 𝜇M) for 1 h, respectively.
Donor characteristics are detailed in Table 1.
At the end of drug incubation, the DCF assay was
performed for the evaluation of potential oxidative stress
induction and the XTT assay was performed for assessment
of the cell viability. Untreated PHH from the same donor
served as control, since they reflect the basal oxidative stress
level of the hepatocytes. Due to large variances between the
reactions of PHH cultures from individual donors towards
the drugs, the results were not merged and are presented on
a case by case basis instead.
The investigation of drug-mediated oxidative stress
induction in PHH revealed that the basal oxidative stress
level varied donor dependently. While donor A and donor
B showed similar ROS concentrations in control cultures
(Figures 4(a1) and 4(b1)), donor C showed a 1.5 times higher
oxidative stress level (Figure 4(c1)). However, all donors
showed a low (donor A and B) to moderate (donor C)
increase of oxidative stress for APAP, but not for DIC
incubation. Investigation of cell viability bymeans of the XTT
assay revealed that stimulation with APAP did not influence
the cell viability, while application of DIC resulted in a clear
increase in cell activity in donor A (Figure 4(a2)) and donor
B (Figure 4(b2)). Donor C (Figure 4(c2)) showed a constant
level in cell activity after drug treatment. All three donors
showed no decrease in cell activity and therefore no loss in
cell viability could be detected.
3.4.2. Kupffer Cell Response to Hepatocyte Stress/Damage. To
evaluate the immunological response of KC after hepatocyte
stress/damage, the isolated KC were stimulated with the
supernatants of PHH having been pretreated with hepato-
toxic drugs (see Section 3.4.1). To evaluate the KC activation,
the cell activity and intracellular ROI formation, the KC
response and the cytokine secretion were measured, respec-
tively. The cell activity increased compound dependently in
KC from all three tested donors (Donor A, Donor B, and
Donor C) after stimulation with supernatants from drug-
treated PHH. The corresponding ROI formation and the
cytokine release as markers for KC activation and response,
respectively, showed donor- and compound-dependent sig-
nals (Figures 5 and 6). Due to these very individual reactions,
the donors were investigated on a case by case basis.
Donor A was a young healthy woman with a benign
liver tumor (Table 1). The activation of KC increased slightly
after stimulationwith supernatants fromAPAP-treated PHH,
compared to the untreated control. In contrast, there was no
increase in cell activity. KC stimulation with DIC did not
lead to any changes neither in the activation measured by
intracellular ROI formation nor in cell activity (Figure 5(a)).
Cytokine release of KC after stimulation with APAP-
treated PHH showed a slight increase in cytokines IL-6 and
TNF-𝛼 but no change in the IL-10 level compared to the
KC stimulation with control hepatocytes. Supernatants from
DIC-treated PHH evoked a notable decrease of the secretion
of IL-6 and TNF-𝛼 in KC cultures. The PGE-2 release in
donor A was comparable to the release in donor B. In both
donors, PGE-2 release decreased drug dependently, whereas
the effect of KC stimulated withDIC-treated PHHwas higher
than after APAP treatment (Figures 6(a) and 6(b)).
Donor B was a 50-year-old man who suffered from a
colorectal liver metastasis (Table 1). The stimulation of KC
with the supernatants of DIC- or APAP-exposed PHH led to
an elevatedKC activation quantified by an increase in the ROI
level and in cell activity (Figure 5(b)).
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Figure 3: APAP-, DIC- or LPS-induced stimulation of KC. APAP (a), DIC (b), or LPS (c) in different concentrations were used for the
stimulation of KC for 24 h. The intracellular ROI formation was investigated by the DCF assay. The detected ROI levels were normalized
to the cell viability measured by means of the XTT assay. Data show means ± SEM.𝑁LPS = 3,𝑁APAP/DIC = 5, 𝑛LPS = 6, and 𝑛APAP/DIC = 2.
Regarding the KC reaction, the stimulation with APAP-
treated PHH showed a slight increase in the release of TNF-
𝛼 comparable to donor A but no effect on the level of IL-
6. After KC stimulation with supernatant from DIC-treated
PHH beside an increase of TNF-𝛼, an increase of the IL-
6 concentration was measured (Figure 6(b)). In terms of
IL-10 secretion, no differences were detected between KC
incubated with supernatant from compound-treated PHH
and those from control hepatocytes (Figure 6(b)).
Donor C was a 57-year-old man with diabetes suffering
from a Klatskin tumor. This rare form of cholangiocellular
carcinoma is closely connected to cholestasis and therefore to
a stress/damage to the affected liver tissue. Additionally, the
patient had previously undergone portal vein embolization
(Table 1). The results of this donor were different from
those of the other two investigated donors. The KC activity
measured by changes in intracellular ROI levels was clearly
decreased after stimulation with supernatant from drug-
treated PHH compared to the stimulationwith that of control
hepatocytes.This decrease in KC activation was more intense
after the stimulation with DIC-treated PHH compared to
the stimulation with APAP-treated PHH (Figure 5(c)). The
effect on the KC activity was inverse. Here, a strong increase
in cellular activity was detected after stimulation of KC with
both compounds.
The KC reaction after stimulation with supernatant from
APAP-treated PHH showed no changes in TNF-𝛼, IL-6, and
IL-10 secretion compared to stimulationwith untreated PHH.
In contrast, the PGE-2 secretion increased noticeably after
treatment with APAP-stimulated PHH. DIC-treated PHH
induced an increase in the release of IL-10 and TNF-𝛼 in
KC. After stimulation of the KC with supernatant from DIC-
treated PHH, the PGE-2 levels decreased comparably in
comparison to the other investigated donors. The IL-6 level
remained unchanged (Figure 6(c)).
4. Discussion
DILI is responsible for severe patientmorbidity andmortality
[31] and, in consequence, causes massive economic losses in
pharmaceutical industry [2]. While different mechanisms of
action are described, there is evidence that the involvement
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Figure 4: Induction of oxidative stress in PHH. PHH from three individual donors (A, B, and C, see Table 1) were treated with 100𝜇M
acetaminophen (APAP) or 100𝜇M diclofenac (DIC) for 1 h. Intracellular ROI formation ((a1), (b1), and (c1)) was investigated by the DCF
assay and the cell activity ((a2), (b2), and (c2)) was determined by the XTT assay. Data are shown as box plots, representing the median, the
interquartile range, and minimum and maximum values, 𝑛 = 4.
of immunologic reactions leading to sensitization reactions
and autoimmune diseases might play a major role [32].
Previous in vivo preclinical testing strategies failed due to the
idiosyncratic nature of DILI causing its low frequencies. The
idiosyncrasy is a result of immunologic reactions in hepatic
inflammation leading in most cases to immune tolerance
towards drug-mediated hepatotoxicity. To bypass systemic
tolerance reactions, we hypothesize that a DILI risk could
be detectable in an in vitro liver model, which enables the
investigation of immunologic cell-cell communication at an
early stage of the hepatotoxic event. Aim of the present study
was the establishment of a human in vitro model for the
simulation of hepatic tissue stress/damage, which allows for
the investigation of immune-mediated signaling in hepatic
inflammatory reactions.
KC are the first cells confrontedwith a hepatic tissue dam-
age. These tissue-resident macrophages sense tissue damage
and cell stress, process incoming signals, and communicate
Mediators of Inflammation 9
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Figure 5:KC activation with supernatants of PHH previously incubated with subtoxic concentrations of hepatotoxic drugs. PHH of three donors
(A, B, and C, see Table 1) were treated with 100𝜇M acetaminophen (APAP) or 100𝜇M diclofenac (DIC) for 1 h. The supernatants were used
to stimulate KC from the same donor for 2 h.The intracellular ROI formation ((a1), (b1), and (c1)) was investigated by the DCF assay and the
KC activity ((a2), (b2), and (c2)) was determined by the XTT assay. Data are shown as box plots, representing the median, the interquartile
range, and minimum and maximum values, 𝑛 = 4.
















































































































































































Figure 6: Secreted cytokine profiles of KC activated with supernatants of PHH previously incubated with subtoxic concentrations of hepatotoxic
drugs. PHH from three donors (A, B, and C; see Table 1) were treated with 100 𝜇M acetaminophen (APAP) or 100 𝜇M diclofenac (DIC) for
1 h.The supernatants were used to stimulate KC from the same donor for 2 h. Inflammatory reactions of KC due to hepatocyte stress/damage
were determined by cytokine analysis in KC supernatants. IL-6 ((a1), (b1), and (c1)), TNF-alpha ((a2), (b2), and (c2)), IL-10 ((a3), (b3), and
(c3)), and PGE-2 ((a4), (b4), and (c4)) were investigated using cytokine ELISAs. Data are shown as box plots, representing the median, the
interquartile range, and minimum and maximum values, 𝑛
(IL-6,TNF-alpha,IL-10) = 4 𝑛(PGE-2) = 2.
a reaction to other NPC and to the systemic immune system
[20, 24, 33].
Therefore, we established a livermodel consisting of PHH
being responsible for displaying the hepatotoxic event andKC
for mediating immunologic cell-cell communication. In the
present study, PHH and KC were successfully isolated from
resected human liver tissue samples. An optimized separation
procedure using an adherence separation step allowed for the
isolation of KC in a high quantity and purity. KC were clearly
identified by detection of the macrophage-specific surface
protein CD68 and by their ability for phagocytosis.
The determination of intracellular ROI formation
revealed that KC are already partially activated after isolation
(initial KC activation). Activated KC produce ROI as part
of the NF-𝜅B signaling pathway, which can be used as a
marker for the determination of the KC activation [34].
Lowest KC activation levels were measured in healthy liver
tissue from young donors with benign tumors and no
secondary diseases or interventions. KC can be activated by
various endogenous sources arising from tissue damage, like
intracellular components, cell debris released by necrosis,
apoptotic bodies [35], and inflammatory cytokines [36]. This
was reflected in KC isolated from liver tissue containing
a resection border with freshly damaged and destroyed
liver tissue. Diseases and medical interventions leading to
hepatic tissue damage may consequently increase the initial
KC activation. We suggest that the correlation of donor
anamnesis to the KC activation level is proportional to the
time span since induction and intensity of the tissue damage,
respectively. The testing of different media supplements to
reduce the initial activation showed that KC activation is not
reversible under the conditions used, although the use of
FCS or of FCS in combination with 𝑛-acetyl cysteine showed
both beneficial effects on KC viability.
However, the results from the additional KC activation
by LPS confirmed that KC can be used for the detection of
inflammatory events when compared to untreated control
cultures. Therefore, an additional activation of KC is possible
and can be quantified by using ROI as a marker for Kupffer
cell activation. Using ROI as a marker for KC activation was
demonstrated previously byUchikura et al. and byHosomura
et al. [18, 30]. In consequence, KC can be used for the
experiments on drug-mediated hepatocyte damage and its
effect on KC.
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Table 2: Summary of KC activation and reaction.
Donor Drug tested ROI formation Cell activity IL-6 TNF-a IL-10 PGF-2
A APAP ↑ — ↑ — — ↓
DIC — — ↓↓ ↓ — ↓↓
B APAP ↑ ↑ — ↑ — ↓
DIC ↑↑ ↑ ↑ ↑ — ↓↓
C APAP ↓ ↑ — — — ↑
DIC ↓↓ ↑↑ — ↑ ↑ ↓↓
↑: slight increase, ↑↑: increase, ↓: slight decrease, ↓↓: decrease, and —: no change.
All data were compared to the control.
The evaluation of the response of KC to drug-mediated
stress/damage in hepatocytes was tested in cultures from
three different donors in two steps: in the first step, PHH
were incubatedwith hepatotoxic compounds (APAPorDIC).
The investigation of drug-mediated oxidative stress revealed
APAP but not DIC-induced oxidative stress in all three
donors.These results are in accordance with those from other
studies showing higher ROS induction for APAP compared
to DIC [26, 37]. However, the evaluation of cell viability
evaluated by measurement of the cell activity showed no
decrease in energy metabolism in PHH cultures after com-
pound treatment. Therefore, the short incubation time and
low concentration represent subtoxic conditions, which can
induce cell stress, but did not lead to irreversible toxic effects.
Moreover, we observed that the amplitude of cell stress was
donor-dependentwith age andpreexistence of a liver damage.
In contrast, incubations of APAP and DIC in KC cultures
from three different donors for 24 h showed no statistically
significant KC activation. These results were plausible due to
the requirement of CYP450 isoenzymes for the hepatotoxic
mode of action of APAP and DIC, which were less expressed
inKC [38]. However, a KC activation for 100 𝜇MofAPAP and
for both compounds for 1mM concentration was observable,
though not statistically significant. Accordingly, we used
100 𝜇M in our main study. The drug is first metabolized by
the PHH before coming in contact with KC. Therefore, far
lower concentrations of remaining parent compounds are
expected in the transferred supernatants. Additionally, we
used much lower incubation times. Therefore, a direct effect
of hepatotoxic compounds onKC from remaining compound
in the supernatants of drug-treated hepatocytes is unlikely.
In the second step, transfer of the supernatant of drug-
treated PHH cultures to corresponding KC cultures revealed
a donor- and compound-dependent activation of KC (see
overview in Table 2). In general, we observed an increased
KC activity correlating with the vulnerability of donors to
hepatotoxicity as seen by APAP-mediated ROS induction.
The KC activation measured on the signaling level demon-
strated a change in ROI formation interpreted as pro- or anti-
inflammatory signaling.
The readout for ROS measurement in PHH and KC
following activation was partly very low and showed an
obvious change only for one donor. Choosing subtoxic
conditions (100𝜇M) to induce cell stress rather than cell
death required short incubation times and low drug con-
centrations [26]. Hepatotoxic effects in this range of drug
concentration are rather mild as shown in 3D coculture liver
models [11]. However, the observed donor- and compound-
dependent activation was confirmed by the measurement of
specific pro- and anti-inflammatory cytokines (see overview
in Table 2). We observed a proinflammatory KC reaction
when supernatant from stressed/damaged hepatocytes from
healthy donor tissue was used. In contrast, an increased con-
centration of anti-inflammatory cytokines was detected if the
supernatant was obtained from liver tissue with a preexisting
liver damage. These results indicate that PHH from older
and diseased donors aremore vulnerable to toxic compounds
than PHH from younger donors. This is in accordance
with observations demonstrating that detoxification capabil-
ities decrease with ongoing age [39]. While healthy donors
showed tendencies towards proinflammatory reactions a
clear anti-inflammatory reaction was observed in a donor
with preliminary tissue damage due to cholestasis as a result
from his tumor. This finding is in accordance with studies
showing that, in chronic or preexisting liver damage, KC
silence an additional inflammatory signal to avoid overre-
action [33, 40, 41]. The observed compound-specific effects
could be due to hapten formation in case of DIC-mediated
hepatotoxicity, which has a stronger impact on KC activation
and reaction than cell stress mediated by ROS formation
from APAP. In this context, KC are capable of detecting
drug-mediated cell stress at an early stage even before cell
damage by hepatotoxicity occurs. In our experimental setup,
only soluble mediators from the PHH supernatant can be
responsible for the induction of the immunologic reactions
in KC, like, for example, cytokines, endogenous proteins,
and haptens. Experiments using hepatotoxic compounds
and their corresponding drug-protein adducts have revealed
a regulating role of KC [33]. Other studies showed KC
activation by cytokines released as a response to different
compounds, like, for example, oncostatin [24], LPS [18, 20], or
HCV-related proteins [30].These data confirm that KC allow
for detection of immunological signals as a first reaction to
drug-mediated hepatocyte stress/damage.
The lownumber of cases of this study is amajor limitation
even though the results were evaluated by means of different
correlating readout parameters. Additionally the use of pri-
mary human cells led to large variations in some experiments,
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for example, the LPS stimulations. Even if we observed clear
trends in our results, statistical significance ismissing in some
cases. We conclude that KC related immunologic reactions
are donor-specific and that the complex in vitro model
consisting of primary human cells is influenced by many
patient-related factors. Therefore, the results have to be
considered on a case by case basis until further donors are
investigated to validate these data.
DILI is described as an idiosyncratic reaction towards
specific drugs and its prediction is difficult [6]. The results
from this study suggest that using KC as detector cells a
hepatotoxic risk can be estimated and reflects compound-
and donor-specific effects.Moreover, this hepatotoxic stress is
alsomeasurable when subtoxic concentrations of hepatotoxic
drugs are investigated.This is the first study using human KC
for detection of hepatotoxic stress/damage induced by DILI
compounds. It is known that existing in vitro models for the
investigation of hepatotoxicity using PHH monocultures are
not capable of reflecting the in vivo toxicity.Themodels suffer
in general from the need of much higher concentrations of
toxic drugs to induce hepatotoxicity compared to the in vivo
situation. The effect on ROS induction leading to cell stress
andKC activation observed for APAPwas less pronounced in
comparison to DIC. We suggest that DIC tends to formation
of protein adducts rather than ROS induction. Classical
hepatotoxicity testing measuring cell viability and oxidative
stress does not capture a DILI risk in this case. Therefore,
cocultures of PHH and KC could be used as a tool for
evaluation of a DILI risk based on different mechanisms
of actions. Using liver cells from different donor groups
would also allow for the investigation of donor-specific
effects. Thus, our established liver model is a useful tool for
the investigation of hepatotoxic effects of DILI compounds
and could contribute to an improved drug safety in drug
development.
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